We are live on ! Find out more
TRAW icon

Traws Pharma

30 hedge funds and large institutions have $3.61M invested in Traws Pharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more call options, than puts

Call options by funds: $32K | Put options by funds: $8K

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

2.14% less ownership

Funds ownership: 11.53% → 9.38% (-2.1%)

12% less funds holding

Funds holding: 34 → 30 (-4)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

66% less capital inflows, than outflows

Capital inflows: $558K | Capital outflows: $1.64M

Holders
30
Holders Change
-4
Holders Change %
-11.76%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
6
Closed
7
Calls
$32​K
Puts
$8​K
Net Calls
+$24​K
Net Calls Change
-⁠$103​K

TRAW Hedge Fund Activity: Q1 2022 in Review

30 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2022, worth a combined $3.61M — down 41% from $6.14M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TRAW and 3 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $349K. The largest seller was Vanguard Group, cutting an estimated $673K.

  • 30 institutional investors held Traws Pharma (TRAW) as of Q1 2022, down from 34 in Q4 2021.
  • Funds reported $3.61M of Traws Pharma stock for Q1 2022, down 41% quarter-over-quarter.
  • 3 funds opened new Traws Pharma positions in Q1 2022 and 7 closed out, a net change of -4 holders.
  • The largest Traws Pharma buyer in Q1 2022 was Renaissance Technologies, an estimated $349K added.
  • The largest Traws Pharma seller in Q1 2022 was Vanguard Group, an estimated $673K sold.

Based on aggregated 13F filings for Q1 2022.